Skip to main content

Table 6 Correlation between Lp-PLA2 level and socio-clinical parameters, Framingham risk score (2008), and liver stiffness score at baseline and at 12 weeks post-treatment

From: The effect of hepatitis C virologic clearance on cardiovascular disease biomarker lipoprotein-associated phospholipase A2 and its relation to serum lipids

Studied parameter Lp-PLA2 (ng/ml)
Pre-treatment correlations Post-treatment correlations
r p R p
Age 0.350 0.001 0.409 <0.001
BMI (kg/m2) 0.331 0.001 0.258 0.014
FBG (mg/dl) 0.353 0.001 0.412 <0.001
HbA1c 0.332 0.001 0.403 <0.001
Platelets (103/훍l) −0.225 0.033 −0.229 0.03
AST (IU/l) 0.188 0.076 0.296 0.005
ALT (IU/l) 0.099 0.355 0.033 0.76
Albumin (g/dl) −0.336 0.001 −0.31 0.003
LDL (mg/dl) 0.142 0.182 0.197 0.062
Total cholesterol (mg/dl) 0.077 0.468 0.043 0.689
HDL (mg/dl) −0.096 0.366 −0.284 0.007
Framingham score 0.669 <0.001 0.677 <0.001
Liver stiffness score (kPa) 0.157 0.139 0.276 0.008
  1. Abbreviations: Lp-PLA2, lipoprotein-associated phospholipase A2; BMI, body mass index; FBG, fasting blood glucose; HbA1c, hemoglobin A1c; AST, aspartate transaminase; ALT, alanine transaminase; LDL, low-density lipoprotein; HDL, high-density lipoprotein